CBER/CDER Reorganization Moving Slowly: Product Decisions Still Pending
Executive Summary
"Phase one" of FDA's reorganization plan for the Center for Biologics Evaluation & Research is still awaiting agreement on which products will be transferred out of the center
You may also be interested in...
CBER Director Goodman Fits New Center Mission, Offers Continuity For Staff
The elevation of Center for Biologics Evaluation & Research Deputy Director Jesse Goodman, MD, to the top position in the center emphasizes continuity during a time of change for FDA's biologics staff
CBER Director Goodman Fits New Center Mission, Offers Continuity For Staff
The elevation of Center for Biologics Evaluation & Research Deputy Director Jesse Goodman, MD, to the top position in the center emphasizes continuity during a time of change for FDA's biologics staff
CBER Director Zoon To Leave FDA In Mid-January To Return To NIH
FDA will be initiating a search for a new head of the reorganized Center for Biologics Evaluation & Research following the departure of Director Kathryn Zoon, PhD, in mid-January